Background. The role of magnetic resonance imaging (MRI) in preoperative planning for women diagnosed with breast cancer remains controversial. The risks and benefits in women with newly diagnosed ductal carcinoma in situ (DCIS) are largely unknown. Patients and Methods. Retrospective chart review comparing women treated for DCIS who did and did not undergo MRI for preoperative planning. End points included number of additional biopsies prompted by MRI, surgical reexcision rates, weight of excisions, mastectomy rates, and conversion to mastectomy after attempted breast conservation. Results. 218 patients met study criteria. Sixty-four patients did not undergo preoperative MRI, and 154 patients did. There was no statistically significant difference (P = not significant, NS) in reexcision rates between the 34.1 % (42/ 123) of women who did and 20/51 (39.2 %) women who did not undergo MRI. Despite use of preoperative MRI, 11/123 women (8.9 %) were converted to mastectomy due to positive margins compared with 4/51 (7.8 %) in the women who did not undergo MRI (P = NS). In women undergoing MRI, average weight of excision at definitive surgery was 49.5 g, while in women who did not undergo MRI, average weight of excision at definitive surgery was 48.7 g. Conclusions. Our data show that MRI does not significantly decrease reexcision rates or conversion to mastectomy after attempted breast-conservation surgery. Based on our findings, we do not believe preoperative MRI adds benefit to the care of this patient population.
Prospective trials are necessary to further investigate the risks and benefits of preoperative MRI in women with DCIS.
The incidence of DCIS diagnosis has increased dramatically since the development of screening mammography guidelines and in an era of improved mammographic sensitivity. Prior to routine mammography, DCIS represented less than 2 % of all diagnosed breast cancers and was usually detected following evaluation of a palpable mass. 1 With the implementation of routine screening mammography, DCIS now represents approximately 25 % of all surgically treated breast cancers. 2 Although DCIS is a nonobligatory precursor to its invasive counterpart, treatment is aggressive and cure rate is excellent with 10-year mortality less than 2 %. 3, 4 MRI has been shown to have greater sensitivity than mammography in the detection of both invasive and noninvasive breast cancer. A 2007 study by Kuhl et al. reviewed over 7,000 women screened with both MRI and mammography at an academic breast center. Review of 167 cases of surgically resected DCIS demonstrated 92 % sensitivity of MRI compared with 56 % sensitivity of mammography. 5 Many studies have also concluded that MRI obtained for preoperative planning detects additional ipsilateral and contralateral disease in a significant number of women.. 6 In 2009, our institution published a retrospective review of 199 cases of invasive breast cancer and the impact of MRI on detection and treatment of additional lesions. In that cohort, MRI detected additional lesions in 37 % of patients. Nineteen percent of the population had additional malignant lesions detected; these additional lesions impacted surgical plans in the majority of cases. 7 These data are consistent with other similar studies. Based on this increased sensitivity of MRI, many centers have implemented routine use for preoperative surgical planning. The purported goal of MRI in this setting is to decrease reexcision rates and increase detection of occult contralateral, multicentric or multifocal disease, although no data have demonstrated a subsequent decrease in recurrence rates when these lesions are detected prior to treatment.
In the absence of MRI, historical reexcision rates for close and positive margins in women with DCIS range from 30 to 70 %. [8] [9] [10] [11] At our institution an estimated 40 % of women with DCIS undergoing breast-conservation surgery require a second operation at an average cost of $11,000 USD per reexcision, before completing definitive surgical management. We hypothesized that use of MRI would decrease reexcision rates and potentially, therefore, decrease the emotional and financial cost of treatment for women with DCIS. We selected these years because attending surgeon staff was stable over this time frame and therefore surgical technique did not impact the data. All patients included in the study had DCIS confirmed by fineneedle or preoperative core biopsy. Women treated with excisional biopsy as an initial diagnostic procedure were excluded. Other exclusion criteria included women initially treated with partial mastectomy at an outside institution who presented to our institution for mastectomy, women with recurrent disease in an irradiated breast for whom breast conservation was not recommended, male breast cancer, women diagnosed on pathology following intended prophylactic mastectomy, and women diagnosed with breast cancer based on MRI detection in the context of high-risk screening. Women diagnosed with invasive cancer in the ipsilateral breast on final pathology were also excluded.
METHODS
We extracted data from all charts including the grade of DCIS, additional MRI lesions identified and number of additional lesions biopsied, number of additional cancers detected by MRI, weight of tissue resected at the primary breast-conserving surgery, number of reexcisions required to achieve negative margins, incidence of conversion to mastectomy due to persistent close or positive margins, and impact of preoperative MRI on surgical planning. During this study period, it was the consensus of the three breast surgeons to reexcise margins on DCIS less than or equal to 1 mm, and to excise fascia in the event of a positive deep margin. This surgical policy was based on the data from Silverstein et al. indicating increased risk of recurrence in patients with DCIS with margins less than 1 mm. 12 All MRIs were obtained on a 1.5-T MR scanner (Signa HDx; GE Healthcare) with use of a dedicated prone eightchannel breast coil (Sentinelle; Sentinelle Medical Inc.). In addition to precontrast T1-and T2-weighted sequences, five sequential postcontrast T1-weighted gradient echo series with fat suppression were obtained following intravenous administration of gadopentetate dimeglumine (Magnevist; Bayer Health Care, Berlin, Germany) and analyzed with enhancement curve analysis CADstream (Confirma) software.
Fisher's exact test was used to calculate the P value of the number converted to mastectomy. T test was used to determine the P value for weight of excision. Chi-square test was used to determine the number of reexcisions after breast-conservation therapy (BCT).
RESULTS
After reviewing 424 charts, 218 unique patients met the inclusion criteria for the study. One hundred fifty-four patients had preoperative MRI, and 64 did not. The majority of the patients, 207, were diagnosed with DCIS following abnormal screening mammogram. Seven patients presented with bloody nipple discharge, and four patients were diagnosed with DCIS in the ipsilateral breast during MRI evaluation of a contralateral invasive breast cancer. MRIs were interpreted by specialized breast imagers. Surgical intervention was performed by three different surgical oncologists, all of whom have at least 10 years of surgical experience. There was no variation in attending surgical or radiology staff during the study period.
Additional lesions were identified in 26/154 (16.9 %) of patients in the MRI group. Four (2.6 %) of these patients opted for mastectomy in lieu of additional biopsies. Three underwent additional imaging, either ultrasound or 6-month MRI depicting benign disease. Nineteen patients (12.5 %) underwent additional biopsies based on MRI findings. Of these biopsies, 10/19 (52.6 %) ultimately confirmed additional sites of disease: 2 patients with invasive carcinoma, 8 patients with additional in situ disease. In eight patients, wider lumpectomies were taken as a result of additional MRI lesions. In this group, the additional lesions on MRI were between 6 mm and 20 mm from the index lesion. In the remaining two patients, multicentric disease was identified, which was managed with double wire localization. MRI for DCIS detected invasive contralateral cancers in 2/154 patients (1.3 %). Both were stage I. One additional patient was diagnosed with contralateral DCIS following MRI for ipsilateral DCIS. Additionally, four patients in this study with DCIS were diagnosed following MRI obtained for contralateral invasive disease.
Overall, 44 patients chose mastectomy as an initial operation. Thirty-two of these women (72.7 %) had undergone MRI, although in the majority (23/44) mastectomy was recommended prior to the MRI based on the extent of disease on mammogram. Twelve women opted for mastectomy although they were deemed candidates for breast-conservation therapy. Eight women opted for mastectomy due to MRI findings [four in whom DCIS was diagnosed following MRI for contralateral invasive cancer and patients therefore opted for bilateral mastectomy, two due to additional MRI lesions which did not undergo biopsy (in both cases lesion 2 was confirmed DCIS at final pathology), and two due to extent of disease identified on MRI although on final pathology one of these patients had minimal residual disease and the other had 1.7 cm of DCIS] (Fig. 1 ). An additional 14 women underwent mastectomy after attempted breast-conservation surgery.
One hundred seventy-four women initially opted for breast-conservation surgery. Despite use of preoperative MRI, 11/123 women (8.9 %) were converted to mastectomy due to positive margins compared with 4/51 (7.8 %) in the women who did not undergo MRI (P = 1). There also was no statistically significant difference in reexcision rates between the MRI (42/123, 34.1 %) and no MRI (20/51, 38.7 %) groups (P = 0.52). Overall weight of excision was also not impacted by use of MRI. In women undergoing MRI, average weight of excision at definitive surgery was 48.7 g, while in women who did not undergo MRI, average weight of excision at definitive surgery was 49.5 g (P = 0.21) ( Table 1 ).
DISCUSSION
Studies have consistently shown that MRI detects breast cancer with increased sensitivity in comparison with mammography alone. A meta-analysis by Houssami et al. reviewing 19 studies of women with breast cancer found that MRI detects additional disease in 16 % of women. This analysis documents that 11.3 % of women underwent more extensive surgery and 8.1 % converted from wide local excision to mastectomy based on the results of MRI performed for preoperative planning. While MRI unquestionably detects additional malignancy in a significant number of patients, the clinical relevance of these cancers is unclear and the false-positive rates of MRI may result in harmful overtreatment. In 1 % of women who underwent mastectomy due to MRI findings in this meta-analysis, no additional cancer was detected at final pathology; in over 5 % of women who underwent more extensive surgeries due to MRI findings, no additional disease was identified on final pathology. 13 In 2010, Turnbull et al. published a randomized trial of over 1,600 women treated for breast cancer in the UK. This study compared MRI versus no MRI before BCT and showed no difference in reoperation rate 6 months after initial surgery.
14 Similarly, a 2011 study from the University of Minnesota showed that preoperative MRI was not associated with a decrease in reexcision rate; this study also demonstrated a nonsignificant trend toward higher mastectomy rates. 15 A 2009 study from the Mayo Clinic also noted a rise in mastectomy rates associated with use of MRI. 17 A more recently published prospective study of 158 women with DCIS found a significantly higher mastectomy rate associated with preoperative MRI and no improvement in reexcision rates (Table 2) . 18 In an era of medical cost containment, reexcisions, which in our institute carry a median charge of $11,104, are both emotionally and fiscally costly. If MRI decreased the likelihood of reexcision, the cost would be justified. Our data are consistent with the few recently published studies, however, showing that preoperative MRI does not decrease reexcision rates in women with DCIS. We found that the need for additional imaging and biopsies increased but the rate of reexcisions and the conversion rate from BCT to mastectomy did not decrease despite the increased sensitivity of MRI. In our cohort, 2/154 women who underwent MRI for DCIS were ultimately diagnosed with higher-stage contralateral cancers (both stage I) as a result of the MRI. The long-term medical, emotional, and financial cost of these potentially missed cancers is unclear. Data presented by Dr. Khan suggest that many of these future contralateral cancers may be effectively (and unknowingly) treated with therapy targeting the known ipsilateral cancer. 19 In our study, consistent with prior studies on this topic, MRI detected additional lesions in 17 % of patients. The majority (19 of 26) underwent additional imaging and biopsies; the remainder either had wider excisions at the time of BCT or elected to proceed with mastectomy. Nearly half of these additional procedures showed no additional disease. In the remainder, the most common finding was DCIS. This is consistent with Housammi's study documenting the positive predictive value of MRI to be 66 % in patients with additional lesions detected on MRI. 13 These findings allow us to conclude that MRI does not benefit the majority or women with DCIS and may cause harm. It is not routinely warranted in the preoperative planning for women with DCIS. This study is limited by its retrospective design, which required extrapolation of counseling and patient decisionmaking based on chart review. During the era in which we did not routinely use MRI for preoperative planning, some patients did selectively undergo MRI based on patient, radiologist or surgeon request. This study is limited in its ability to ascertain which patients had selective MRIs, and the characteristics of this group may have impacted the data. A prospective study is necessary to fully examine decisionmaking around breast conservation and mastectomy, and the role MRI plays in the counseling and management of women with DCIS. Such a study may identify a subset of women in whom MRI is indicated, for example, extremely or heterogeneously dense-breasted women or women with strong family history without a known mutation; our study was not designed with this intent.
DCIS accounts for nearly 25 % of the breast surgeries performed annually in the USA. It is a prevalent and curable disease. The additional surgical procedures performed based on MRI findings add cost and delay treatment in many cases. Based on our data, MRI does not decrease reexcision rates or conversion to mastectomy rates. Based on the data from other authors, MRI results in increased ipsilateral and contralateral mastectomy rates. In an era in which it is imperative to deliver quality, cost-effective care, the value of MRI as a routine diagnostic procedure in women diagnosed with DCIS has not been demonstrated.
